Gilead Sciences (GILD)

Company Profile

Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California. Gilead has promoted equity, particularly healthcare equity, since the company brought its first therapies to the market. Through global partnerships, Gilead's medicines today reach millions of people in low- and middle-income countries around the world. In the United States, Gilead has committed more than $100 million over 10 years through the COMPASS Initiative to community organizations that are working to combat HIV in the Southern United States. In 2020, Gilead launched the Racial Equity Community Impact Fund to support organizations tackling racial inequities affecting Black communities across the United States.

Company profile

Ticker

GILD

Exchange

NASDAQ

Website

www.gilead.com

CEO

Daniel O'Day

Incorporated

Delaware

Location

California

Fiscal year end

Dec 31

Sector

Manufacturing > Biological Product (except Diagnostic) Manufacturing

Industry (SIC)

Biological Products, (No Diagnostic Substances)

AMGEN • Biogen • Qiagen • Moderna • BioNTech SE • Bio-Techne • Sana Biotechnology • Ginkgo Bioworks • Exelixis • Acorda Therapeutics ...

Former names

GILEAD SCIENCES INC

SEC CIK

0000882095

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Indentures

Material Contracts & Credit Agreements

Subsidiaries Lists

Subsidiaries

Asegua Therapeutics LLC • Forty Seven, Inc. • Forty Seven Holdings, LLC • Gilead Alberta, LLC • Gilead Apollo, LLC • Gilead Biopharmaceutics US LLC • Gilead Calistoga, LLC • Gilead Connecticut, Inc. • Gilead Holdings, LLC • Gilead Pharmasset LLC ...

IRS number

943047598

GILD stock data

1M 1Y 5Y

Analyst ratings and price targets

Last 3 months

Average target

$91.33

Low target

$86.00

High target

$100.00

Latest filings (excl ownership)

View all

8-K

Departure of Directors or Certain Officers

3 May 23

Gilead Sciences Announces First Quarter 2023 Financial Results

27 Apr 23

CORRESP

Correspondence with SEC

25 Apr 23

PX14A6G

Letter to shareholders

Letter to shareholders

23 Mar 23

Transcripts

View all

GILD

Earnings call transcript

2023 Q1

27 Apr 23

GILD

Earnings call transcript

2022 Q4

2 Feb 23

GILD

Earnings call transcript

2022 Q3

28 Oct 22

GILD

Earnings call transcript

2022 Q2

2 Aug 22

GILD

Earnings call transcript

2022 Q1

29 Apr 22

GILD

Earnings call transcript

2021 Q4

2 Feb 22

GILD

Earnings call transcript

2021 Q3

29 Oct 21

GILD

Earnings call transcript

2021 Q2

30 Jul 21

GILD

Earnings call transcript

2021 Q1

30 Apr 21

GILD

Earnings call transcript

2021 Q1

29 Apr 21

Latest ownership filings

View all

Financial summary

Financial statements Chart GILD financial data

Quarter (USD)	Mar 23	Dec 22	Sep 22	Jun 22
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 22	Dec 21	Dec 20	Dec 19
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	4.94 bn	4.94 bn	4.94 bn	4.94 bn	4.94 bn	4.94 bn
Cash burn (monthly)	158.67 mm	(no burn)	(no burn)	(no burn)	(no burn)	(no burn)
Cash used (since last report)	355.64 mm	n/a	n/a	n/a	n/a	n/a
Cash remaining	4.58 bn	n/a	n/a	n/a	n/a	n/a
Runway (months of cash)	28.9	n/a	n/a	n/a	n/a	n/a

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q1 2023

GILD institutional ownership history Ownership history

81.5% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	1672	1718	-2.7%
Opened positions	116	277	-58.1%
Closed positions	162	126	+28.6%
Increased positions	641	544	+17.8%
Reduced positions	684	715	-4.3%

13F shares	Current	Prev Q	Change
Total value	83.90 tn	87.96 tn	-4.6%
Total shares	1.02 bn	1.03 bn	-0.8%
Total puts	7.56 mm	12.04 mm	-37.2%
Total calls	8.07 mm	11.96 mm	-32.5%
Total put/call ratio	0.9	1.0	-7.0%

Largest owners	Shares	Value	Change
BLK Blackrock	126.56 mm	$10.50 tn	-3.8%
Vanguard	112.97 mm	$9.37 tn	+0.8%
Capital World Investors	76.50 mm	$6.35 tn	+11.0%
Capital Research Global Investors	58.28 mm	$4.84 tn	+6.7%
STT State Street	57.80 mm	$4.80 tn	-1.9%
Dodge & Cox	34.70 mm	$2.88 tn	-3.3%
Geode Capital Management	23.77 mm	$1.97 tn	-0.3%
FMR	20.91 mm	$1.73 tn	+27.2%
BK Bank Of New York Mellon	17.01 mm	$1.41 tn	+2.8%
MS Morgan Stanley	16.11 mm	$1.34 tn	-6.3%

Largest transactions	Shares	Bought/sold	Change
Norges Bank	0.00	-12.99 mm	EXIT
Capital World Investors	76.50 mm	+7.61 mm	+11.0%
BLK Blackrock	126.56 mm	-5.00 mm	-3.8%
FMR	20.91 mm	+4.47 mm	+27.2%
Envestnet Asset Management	6.64 mm	+3.92 mm	+143.5%
Capital Research Global Investors	58.28 mm	+3.68 mm	+6.7%
Capital International Investors	6.86 k	-3.65 mm	-99.8%
Millennium Management	0.00	-3.30 mm	EXIT
Alliancebernstein	6.99 mm	+3.10 mm	+79.6%
Neuberger Berman	2.81 mm	+2.59 mm	+1191.3%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

GILD insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
3 May 23	Welters Anthony	Common Stock	Grant	Acquire A	No	No	0	1,887	0.00	7,922
3 May 23	Welters Anthony	NQSO Common Stock	Grant	Acquire A	No	No	79.45	10,173	808.24 k	10,173
3 May 23	Manwani Harish	Common Stock	Payment of exercise	Dispose F	No	No	79.45	368	29.24 k	11,014
3 May 23	Manwani Harish	Common Stock	Grant	Acquire A	No	No	0	1,887	0.00	11,382
3 May 23	Manwani Harish	NQSO Common Stock	Grant	Acquire A	No	No	79.45	10,173	808.24 k	10,173
3 May 23	Rodriguez Javier	Common Stock	Grant	Acquire A	No	No	0	1,887	0.00	8,392
3 May 23	Rodriguez Javier	NQSO Common Stock	Grant	Acquire A	No	No	79.45	10,173	808.24 k	10,173
3 May 23	Lofton Kevin E	Common Stock	Grant	Acquire A	Yes	No	0	1,887	0.00	92,653
3 May 23	Lofton Kevin E	NQSO Common Stock	Grant	Acquire A	No	No	79.45	10,173	808.24 k	10,173
3 May 23	Horning Sandra	Common Stock	Grant	Acquire A	No	No	0	1,887	0.00	3,631